(Incorporated in Nevada)

We are an early-stage uranium enrichment company focused on the development of patented and other proprietary laser-based uranium enrichment technologies and related capabilities for the production of enriched uranium to service the growing needs of the U.S. domestic and international nuclear energy industry. Our proprietary technology encompasses the Condensation Repression Isotope-Selective Laser Activation (“CRISLA”) process, and other proprietary processes and systems (which we refer to as the “LIST technology”).

Enriched uranium is a key component used in the manufacture of nuclear fuel for commercial nuclear power reactors and other nuclear energy applications. Due to increasing global demand for nuclear energy and the U.S. and other nations’ focus on next generation nuclear power technologies, the development and expansion of nuclear reactors are expected to continue. As new nuclear reactors are designed, constructed, and brought into operation, demand for nuclear fuel, including enriched uranium, is anticipated to increase accordingly.

Our target markets include operators of commercial light-water reactors (“LWRs”) as well as developers and operators of advanced nuclear reactor technologies, including small modular reactors (“SMRs”) and microreactors (“MMRs”). Subject to obtaining the necessary regulatory approvals and developing commercial-scale operations, we intend to produce and supply enriched uranium to participants in our target markets.

In December 2025, we received a radiological material license (the “Radiological Material License”) from the State of Tennessee to start Phase 1 and Phase 2 (each as defined below) of our development plan in our test demonstration facility in Oak Ridge, Tennessee (the “Oak Ridge Test Demonstration Facility”). This Radiological Material License authorizes us to conduct certain laboratory-scale activities involving radioactive materials. A cylinder of UF₆ was delivered to our Oak Ridge Test Demonstration Facility in October 2026, and experiments are expected to begin before the end of 2026. Further, in October 2026, the U.S. Nuclear Regulatory Commission (“NRC”) approved our Standard Practice Procedures Plan (SPPP) for our Oak Ridge Test Demonstration Facility. The proposed SPPP was found to provide reasonable assurance that we will adequately protect classified matter and sensitive information in our possession. This SPPP is contingent and will be considered active upon a successful NRC operational readiness review which will take place in due course.

We are also required to receive a license from the NRC prior to constructing and operating a commercial uranium enrichment facility. NRC licenses uranium enrichment facilities and authorizes the possession and use of nuclear materials, ensuring that proposed equipment, facilities, and safety controls meet federal requirements for public health, environmental protection, and national security. As of the date of this prospectus, other than as described above, we do not hold any other licenses or approvals from the NRC or other regulatory authorities. We have not yet commenced commercial production or sales of enriched uranium.

Note: LIS Technologies, Inc. has not generated any revenue since inception, according to the prospectus.

(Note: LIS Technologies, Inc. filed its S-1 for its small IPO and disclosed the terms: 2.83 million shares at a price range of $5.00 to $7.00 to raise $16.98 million, if priced at the $6.00 mid-point of its range.)